SIGA - White House making additional 50K courses of antiviral Tpoxx available to states for monkeypox

• The Biden administration Thursday said it is making available 50K treatment courses of SIGA Technologies' Tpoxx (tecovirimat) to jurisdictions next week.
• The antiviral is approved for treatment of smallpox, but can also be used for monkeypox under the US FDA's Expanded Access protocol.
• The White House said that the 50K courses -- nearly five times more than the confirmed number of monkeypox cases in the US -- are being released so they can be prepositioned for easier patient access to the medication.
• Allocation will be based 75% on the number of cases in a jurisdiction and 25% on the number of individuals who are at the highest risk of contracting the virus.
• SIGA ( NASDAQ: SIGA ) is set to begin human trials of Tpoxx for monkeypox in the UK next week .

For further details see: